New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 28, 2012
18:22 EDTBMY, PFE, PPHMOn The Fly: After Hours Movers
HIGHER: Bristol Myers Squibb (BMY), up 2%, and Pfizer (PFE), up 0.60% after the companies won FDA approval for their anti-clotting drug Eliquis... LOWER: Peregrine Pharmaceuticals (PPHM), down 8.9% after filing a $75M at-the-market secondary.
News For BMY;PFE;PPHM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 16, 2014
08:42 EDTBMYBristol-Myers upgraded at BMO Capital
Subscribe for More Information
08:38 EDTPFEBaxter expects divestiture of vaccines business to Pfizer to close in Q4
Subscribe for More Information
08:08 EDTPFEActavis confirms generic Quillivant XR patent challenge
Subscribe for More Information
07:28 EDTPFEFDA to hold a joint advisory committee meeting on Chantix
Subscribe for More Information
06:16 EDTBMYBristol-Myers upgraded to Outperform from Market Perform at BMO Capital
October 15, 2014
15:00 EDTPFEShire-Allergan, AbbVie-Pfizer deals possible if merger scrapped, Bloomberg says
Subscribe for More Information
12:36 EDTPPHMOn The Fly: Midday Wrap
Subscribe for More Information
10:49 EDTPPHMEbola linked names rise again amid broader market sell-off
Subscribe for More Information
10:49 EDTPPHMHigh option volume stocks
High option volume stocks: SNV FCG TXT MDSO PPHM NTRS CCL RGP LLTC SOCL
09:57 EDTBMYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:20 EDTPPHMOn The Fly: Pre-market Movers
Subscribe for More Information
08:38 EDTPPHMPeregrine up 21% after saying will examine drug as potential Ebola treatment
08:15 EDTPPHMPeregrine says data support Phosphatidylserine as potential target in Ebola
Peregrine Pharmaceuticals announced the publication of a peer-reviewed manuscript, to appear in the Vaccines and Therapies for Biodefense Agents special edition of the peer-reviewed Journal of Immunology Research in a manuscript titled: "Effective Binding of a Phosphatidylserine-Targeting Antibody to Ebola Virus Infected Cells and Purified Virions," related to preclinical research demonstrating that the company's lead drug candidate bavituximab, a phosphatidylserine-targeting antibody, exhibits specific and strong binding to Ebola virions and Ebola virus-infected cells in vitro. Cyril Empig, Ph.D., associate research director at Peregrine Pharmaceuticals, said, "Our goal with this work was to continue exploring the potential of bavituximab in the antiviral arena and in this case, specifically in biodefense applications. With the increased focus on Ebola, there is an opportunity to take advantage of the specificity of bavituximab for Ebola virus and develop therapeutics or treatment regimens that could neutralize the virus. In addition, recently reported genomic sequence variations in EBOV suggest that drugs targeting specific viral non-variant proteins or protein sequences are at risk of failure as a result of virus escape mutations...Given these data, we are developing a plan to explore potential applications of bavituximab and PS-targeting antibodies in the treatment of Ebola."
October 14, 2014
11:23 EDTBMY, PFEBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 13, 2014
08:05 EDTBMYBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
08:01 EDTPFEPfizer announces FDA acceptance of Palbociclib NDA with priority review
Subscribe for More Information
07:13 EDTBMYBioFlorida to hold a conference
Subscribe for More Information
October 10, 2014
10:03 EDTBMYBristol-Myers receives orphan status for melanoma treatment
Subscribe for More Information
08:19 EDTBMYMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
08:06 EDTPFEPfizer presents Staphylococcus aureus vaccine Phase 1, Phase 2 study data
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use